Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Recruiting now · Phase 2

Conditions studied: Dyslipidemias

In brief

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Key facts

Study ID

NCT06496243

Run by

NewAmsterdam Pharma

People needed

69

Starts

2024-12-02

Expected to finish

2027-02-01

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lp(a): >=50 mg/dL (>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) >= 20 mg/dL (>= 50 nmol/L) to <50 mg/dL (< 125 nmol/L) for cohort 2
• LDL-C >70 mg/dL
• TG < 400mg/dL (<4.52 mmol/L)

You may not qualify if…

• HbA1c>=10 or FPG >=270 mg/dL
• CV events within 3 months of screen

Where it is running

• UPenn — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.